Unknown

Dataset Information

0

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.


ABSTRACT: B7-H4 protein is frequently overexpressed in ovarian cancer. Here, we engineered T cells with novel B7-H4-specific chimeric antigen receptors (CARs) that recognized both human and murine B7-H4 to test the hypothesis that B7-H4 CAR T cell therapy can be applied safely in preclinical models. B7-H4 CAR T cells specifically secreted IFN-? and lysed B7-H4(+) targets. In vivo, B7-H4 CAR T cells displayed antitumor reactivity against B7-H4(+) human ovarian tumor xenografts. Unexpectedly, B7-H4 CAR T cell treatment reproducibly showed delayed, lethal toxicity 6-8 weeks after therapy. Comprehensive assessment of murine B7-H4 protein distribution uncovered expression in ductal and mucosal epithelial cells in normal tissues. Postmortem analysis revealed the presence of widespread histologic lesions that correlated with B7-H4(+) expression, and were inconsistent with graft versus host disease. Lastly, expression patterns of B7-H4 protein in normal human tissue were comparable to distribution in mice, advancing our understanding of B7-H4. We conclude that B7-H4 CAR therapy mediates control of cancer outgrowth. However, long-term engraftment of B7-H4 CAR T cells mediates lethal, off-tumor toxicity that is likely due to wide expression of B7-H4 in healthy mouse organs. This model system provides a unique opportunity for preclinical evaluation of safety approaches that limit CAR-mediated toxicity after tumor destruction in vivo.

SUBMITTER: Smith JB 

PROVIDER: S-EPMC5154474 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.

Smith Jenessa B JB   Lanitis Evripidis E   Dangaj Denarda D   Buza Elizabeth E   Poussin Mathilde M   Stashwick Caitlin C   Scholler Nathalie N   Powell Daniel J DJ  

Molecular therapy : the journal of the American Society of Gene Therapy 20160721 11


B7-H4 protein is frequently overexpressed in ovarian cancer. Here, we engineered T cells with novel B7-H4-specific chimeric antigen receptors (CARs) that recognized both human and murine B7-H4 to test the hypothesis that B7-H4 CAR T cell therapy can be applied safely in preclinical models. B7-H4 CAR T cells specifically secreted IFN-γ and lysed B7-H4(+) targets. In vivo, B7-H4 CAR T cells displayed antitumor reactivity against B7-H4(+) human ovarian tumor xenografts. Unexpectedly, B7-H4 CAR T ce  ...[more]

Similar Datasets

| S-EPMC7546952 | biostudies-literature
| S-EPMC5870586 | biostudies-literature
| S-EPMC3581823 | biostudies-literature
| S-EPMC5581684 | biostudies-literature
| S-EPMC7906752 | biostudies-literature
| S-EPMC4411454 | biostudies-literature
| S-EPMC3898118 | biostudies-literature
| S-EPMC5939565 | biostudies-literature
| S-EPMC4733371 | biostudies-other
| S-EPMC10505056 | biostudies-literature